These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 16798763)
1. Cardiac resynchronization pacing without defibrillator capability: is this a viable option? Ermis C; Benditt DG Europace; 2006 Jul; 8(7):499-501. PubMed ID: 16798763 [TBL] [Abstract][Full Text] [Related]
2. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C; J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193 [TBL] [Abstract][Full Text] [Related]
3. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447 [TBL] [Abstract][Full Text] [Related]
4. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. Yannopoulos D; Lurie KG; Sakaguchi S; Milstein S; Ermis C; VanHeel L; Benditt DG J Am Coll Cardiol; 2007 Sep; 50(13):1246-51. PubMed ID: 17888841 [TBL] [Abstract][Full Text] [Related]
5. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867 [TBL] [Abstract][Full Text] [Related]
6. Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy? Pieragnoli P; Ricciardi G; Colella A; Musilli N; Porciani MC; Giaccardi M; Padeletti L; Michelucci A Minerva Cardioangiol; 2006 Dec; 54(6):735-41. PubMed ID: 17167385 [TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Linde C; Gold M; Abraham WT; Daubert JC; Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890 [TBL] [Abstract][Full Text] [Related]
8. Cardiac resynchronization therapy: a review of CRT-D versus CRT-P. Stabile G; Iuliano A; Turco P; Ciardiello C; De Simone A Future Cardiol; 2009 Nov; 5(6):567-72. PubMed ID: 19886783 [TBL] [Abstract][Full Text] [Related]
9. Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator. Lepillier A; Piot O; Gerritse B; Copie X; Lavergne T; Paziaud O; Lascault G; Waintraub X; Otmani A; Le Heuzey JY Europace; 2009 Jan; 11(1):80-5. PubMed ID: 18952828 [TBL] [Abstract][Full Text] [Related]
10. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. Uretsky BF; Thygesen K; Daubert JC; Erdmann E; Freemantle N; Gras D; Kappenberger L; Tavazzi L; Cleland JG J Card Fail; 2008 Oct; 14(8):670-5. PubMed ID: 18926439 [TBL] [Abstract][Full Text] [Related]
11. [Cardiac resynchronization therapy with defibrillation capability: considerations on a not yet proven therapeutic superiority]. Berisso MZ; Canonero D; Caruso D; Setti S; Domenicucci S G Ital Cardiol (Rome); 2010 Apr; 11(4):295-305. PubMed ID: 20677575 [TBL] [Abstract][Full Text] [Related]
12. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403 [TBL] [Abstract][Full Text] [Related]
13. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827 [TBL] [Abstract][Full Text] [Related]
14. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience. Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992 [TBL] [Abstract][Full Text] [Related]
15. CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. Aronow WS Geriatrics; 2005 Feb; 60(2):24, 26-8. PubMed ID: 15742919 [TBL] [Abstract][Full Text] [Related]
16. Effect of cardiac resynchronization therapy in patients with moderate left ventricular systolic dysfunction and wide QRS complex: a prospective study. Fung JW; Zhang Q; Yip GW; Chan JY; Chan HC; Yu CM J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1288-92. PubMed ID: 16987381 [TBL] [Abstract][Full Text] [Related]
17. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768 [TBL] [Abstract][Full Text] [Related]
18. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale. Martin DO; Stolen KQ; Brown S; Yu Y; Christie C; Doshi SK; Smith JM; Gold MR; Day JD Am Heart J; 2007 Jan; 153(1):7-13. PubMed ID: 17174627 [TBL] [Abstract][Full Text] [Related]
19. Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure? Turley AJ; Raja SG; Salhiyyah K; Nagarajan K Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1141-6. PubMed ID: 18541605 [TBL] [Abstract][Full Text] [Related]
20. Triple-site versus standard cardiac resynchronization therapy study (TRUST CRT): clinical rationale, design, and implementation. Lenarczyk R; Kowalski O; Sredniawa B; Pruszkowska-Skrzep P; Pluta S; Sokal A; Kukulski T; Stabryła-Deska J; Woźniak A; Kowalczyk J; Zielińska T; Mazurek M; Streb W; Zembala M; Kalarus Z J Cardiovasc Electrophysiol; 2009 Jun; 20(6):658-62. PubMed ID: 19635069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]